Punicalagin alleviates hypercholesterolemia in mice through modulating farnesoid X receptor signaling and modulating gut microbiota

Punicalagin has been demonstrated to exhibit anti-oxidant and anti-infl ammatory properties, but whether and how it could impact hypercholesterolemia remains not fully explored. The aim of this study was to investigate the influence of punicalagin on hypercholesterolemia in mice and its related mechanisms. After 6 weeks’ intervention, punicalagin significantly reduced serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels in mice fed a high-fat high-cholesterol (HFHC) diet. Meanwhile, punicalagin supplementation lowered hepatic cholesterol level, which corresponded to the down-regulation of cholesterol synthesis genes (Fdps, Cyp51) and up-regulated bile acid synthesis genes (Cyp7a1, Cyp27a1). In addition, bile acid reabsorption was retarded in punicalagin-fed mice through down-regulating ileal apical sodium-dependent BA transporter (ASBT). Furthermore, i ntestinal farnesoid X receptor (FXR)-fibroblast growth factor 15 (Fgf15) pathway was inhibited while hepatic FXR-small heterodimeric partner (SHP) pathway was activated in punicalagin group. M icrobiota analysis and targeted metabolomics showed that p unicalagin decreased the abundance of bile-salt hydrolase (BSH)-producing bacteria (Clostridiaceae and Bifidobacteriaceae) and the ratio of primary BAs to secondary BAs. In conclusion, the cholesterol-lowering effect of punicalagin partly through down-regulating cholesterol synthesis and increasing cholesterol catabolism, which could be achieved by regulating gut microbiota, altering bile acid composition and modulating FXR signaling pathway. T hese findings indicate the potential application of punicalagin-related products as an alternative strategy for hypercholesterolemia prevention and mitigation.